What's happening
across the portfolio
- CinDome Pharma
CinDome Pharma Announces Completion of Enrollment in the envisionGI Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis
CinDome announced the completion of patient enrollment in its envisionGI Phase 2 clinical study evaluating deudomperidone (CIN-102) for the treatment of idiopathic gastroparesis.
Read story - CinDome Pharma
CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis
CinDome announced enrollment completion in its envision3D Phase 2 trial evaluating deudomperidone (CIN-102) for the treatment of diabetic gastroparesis.
Read story - CinDome Pharma
CinDome Pharma Announces First Patient Dosed in Clinical Trial of Deudomperidone (CIN-102)
CinDome announced the dosing of the first patient in its clinical trial of deudomperidone (CIN-102) for the treatment of idiopathic gastroparesis.
Read story - CinRx
CinRx Pharma Announces Additional $73 Million Financing
CinRx Pharma announced an additional $73 million financing to further capitalize its portfolio of asset-focused subsidiary companies and accelerate clinical execution across multiple programs.
Read story - CinDome Pharma
CinDome Pharma Announces $40 Million Series B Extension
CinDome Pharma announced a $40 million Series B extension to support continued clinical development of deudomperidone (CIN-102) for the treatment of gastroparesis.
Read story
Let's advance medicine, together
Whether you're a clinical investigator, a potential partner, or considering joining our team - we'd like to hear from you.